Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP diet and health study

American Journal of Epidemiology

Volumn 178, Issue 3, 2013, Pages 359-371

  Nyante, Sarah J ^a   Dallal, Cher M ^a   Gierach, Gretchen L ^a   Park, Yikyung ^a   Hollenbeck, Albert R ^b   Brinton, Louise A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AARP   (United States)

Author keywords

breast neoplasms; cohort studies; histology; risk factors

Indexed keywords

CANCER; DIET; HEALTH RISK; HETEROGENEITY; HISTOPATHOLOGY; HORMONE; RISK FACTOR; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RISK; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK FACTOR; SELF CONCEPT;

BREAST NEOPLASMS; COHORT STUDIES; HISTOLOGY; RISK FACTORS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; ANTHROPOMETRY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; CONFIDENCE INTERVALS; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MATERNAL AGE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM GRADING; NEOPLASM STAGING; POSTMENOPAUSE; QUESTIONNAIRES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; UNITED STATES;

EID: 84881180973     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws471     Document Type: Article

References (46)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. (http://seer.cancer.gov/csr/1975-2008/). (Accessed August 23, 2011).
2. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9): 1046-1052.
3. Rosen PP. Rosen's Breast Pathology. Philadelphia, PA: Lippincott-Raven; 1997.
4. Holland DW, Boucher LD, Mortimer JE. Tubular breast cancer experience atWashington University: a review of the literature. Clin Breast Cancer. 2001;2(3):210-214.
5. Liu GF, Yang Q, Haffty BG, et al. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2009; 75(5):1304-1308.
6. Cho LC, Hsu YH. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung J Med Sci. 2008;24(5):227-232.
7. Barkley CR, Ligibel JA,Wong JS, et al. Mucinous breast carcinoma: a large contemporary series. Am J Surg. 2008; 196(4):549-551.
8. Anderson WF, Pfeiffer RM, Dores GM, et al. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1899-1905.
9. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003;163(18):2149-2153.
10. LouwmanMW, Vriezen M, van Beek MW, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121(1):127-135.
11. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541-547.
12. Cao AY, He M, Liu ZB, et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol. 2012; 19(9):3019-3027.
13. Vo T, Xing Y, Meric-Bernstam F, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007; 194(4):527-531.
14. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20(6):479-489.
15. Wohlfahrt J, Mouridsen H, Andersen PK, et al. Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer. 1999;81(1):49-55.
16. Reeves GK, Pirie K, Green J, et al. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009;100(3): 538-544.
17. Work ME, Andrulis IL, John EM, et al. Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2012;134(3):1209-1220.
18. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7(11): 910-918.
19. Garcia-Closas M, Brinton LA, Lissowska J, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006;95(1):123-129.
20. Rosenberg LU, Magnusson C, Lindstrom E, et al. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 2006;8(1):R11.
21. Li CI, Daling JR, Malone KE, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(5):946-954.
22. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933-941.
23. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001;154(12):1119-1125.
24. Michaud D, Midthune D, Hermansen S, et al. Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manag. 2005;32(2):70-75.
25. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, Third Edition. Geneva, Switzerland: World Health Organization; 2000.
26. WHO Expert Committeee on Physical Status. The Use and Interpretation of Anthropometry: Report of a WHO Expert Technical Committee. (WHO technical report series, no. 854). Geneva, Switzerland:World Health Organization; 1995:312-344.
27. Lew JQ, Freedman ND, Leitzmann MF, et al. Alcohol and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. Am J Epidemiol. 2009;170(3):308-317.
28. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771.
29. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control. 2006;17(5): 695-703.
30. Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer. 2006;118(5):1292-1301.
31. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: theWomen's Health Initiative (United States). Cancer Causes Control. 2002; 13(8):741-751.
32. Stalsberg H, Thomas DB, Noonan EA. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1989; 44(3):399-409.
33. Ma H, Bernstein L, Pike MC, et al. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
34. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
35. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727.
36. Malone KE, Daling JR,Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev. 1993;15(1):80-97.
37. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
38. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19):10869-10874.
39. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
40. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
41. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
42. Shibuta K, Ueo H, Furusawa H, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer. 2011;18(4):292-298.
43. Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 2010; 222(3):282-298.
44. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 2009;22(11):1401-1414.
45. Lopez-Garcia MA, Geyer FC, Natrajan R, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtypematched ductal and lobular carcinomas. J Pathol. 2010; 222(1):64-75.
46. Capella C, Eusebi V, Mann B, et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology. 1980; 4(6):613-630.